These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21352258)

  • 61. Gene Expression Profiling for Melanoma Prognosis: Going Beyond What We See With Our Eyes.
    Ngo BT
    Cutis; 2023 May; 111(5):222-223. PubMed ID: 37406321
    [No Abstract]   [Full Text] [Related]  

  • 62. Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.
    Arias-Mejias SM; Quattrocchi E; Tempel D; Luna-Vargas M; Chen J; Murphree DH; Gjorgova Gjeorgjievski S; Lehman JS; Bridges AG; Dwarkasing J; Meves A
    Int J Dermatol; 2020 Nov; 59(11):e431-e433. PubMed ID: 32516450
    [No Abstract]   [Full Text] [Related]  

  • 63. Re: Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
    Kawada T
    Eur J Cancer; 2021 Nov; 157():516-517. PubMed ID: 34420836
    [No Abstract]   [Full Text] [Related]  

  • 64. The Role of Clinicopathologic Nomograms for Melanoma in the Era of Gene Expression Profiling.
    Tripathi R; Larson K; Fowler G; Vetto JT; Bordeaux JS; Yu WY
    Ann Surg Oncol; 2023 Oct; 30(11):6359-6360. PubMed ID: 37369885
    [No Abstract]   [Full Text] [Related]  

  • 65. The letter responds to comment on Identification of stage I/IIA melanoma patients at high risk of disease relapse using a clinicopathologic and gene expression model.
    Eggermont AMM; Bellomo D; Dwarkasing J; Meerstein-Kessel L; Meves A
    Eur J Cancer; 2021 Nov; 157():518-519. PubMed ID: 34565669
    [No Abstract]   [Full Text] [Related]  

  • 66. Reply to Problematic methodology in a systematic review and meta-analysis of DecisionDx-Melanoma.
    Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
    J Am Acad Dermatol; 2020 Nov; 83(5):e359-e360. PubMed ID: 32526325
    [No Abstract]   [Full Text] [Related]  

  • 67. Training in molecular cytopathology.
    da Cunha Santos G; Saieg MA; Tsao MS
    Cytopathology; 2013 Jun; 24(3):205-7. PubMed ID: 23711183
    [No Abstract]   [Full Text] [Related]  

  • 68. Response from C. Clinton and D.P. Boyd.
    Clinton C; Boyd DP
    Cytopathology; 2013 Jun; 24(3):207. PubMed ID: 23858528
    [No Abstract]   [Full Text] [Related]  

  • 69. Reply to Reimann et al.
    Clarke LE; Leachman SA
    Mod Pathol; 2019 May; 32(5):725-727. PubMed ID: 30666051
    [No Abstract]   [Full Text] [Related]  

  • 70. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.
    Gross A; Niemetz-Rahn A; Nonnenmacher A; Tucholski J; Keilholz U; Fusi A
    Target Oncol; 2015 Mar; 10(1):77-84. PubMed ID: 24824730
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
    Amaro A; Mirisola V; Angelini G; Musso A; Tosetti F; Esposito AI; Perri P; Lanza F; Nasciuti F; Mosci C; Puzone R; Salvi S; Truini M; Poggi A; Pfeffer U
    Eur J Cancer; 2013 Oct; 49(15):3353-65. PubMed ID: 23849826
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells.
    Pietraszek-Gremplewicz K; Simiczyjew A; Dratkiewicz E; Podgórska M; Styczeń I; Matkowski R; Ziętek M; Nowak D
    J Cell Mol Med; 2019 Dec; 23(12):8453-8463. PubMed ID: 31638339
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rates of
    Gottesdiener LS; O'Connor S; Busam KJ; Won H; Solit DB; Hyman DM; Shoushtari AN
    Clin Cancer Res; 2018 Dec; 24(23):5815-5819. PubMed ID: 30093446
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.
    Meriggi F; Vermi W; Bertocchi P; Zaniboni A
    Rev Recent Clin Trials; 2014; 9(1):8-12. PubMed ID: 24758538
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.
    Gabriel EM; Necela B; Bahr D; Vivekanandhan S; Shreeder B; Bagaria S; Knutson KL
    Sci Rep; 2024 Oct; 14(1):24545. PubMed ID: 39427012
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas.
    Parisi F; Aurisicchio L; Pecorari A; Poli A; Millanta F
    Animals (Basel); 2024 May; 14(10):. PubMed ID: 38791617
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
    Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence.
    Čižmáriková M; Michalková R; Mirossay L; Mojžišová G; Zigová M; Bardelčíková A; Mojžiš J
    Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002335
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells.
    Simiczyjew A; Wądzyńska J; Kot M; Ziętek M; Matkowski R; Hoang MP; Donizy P; Nowak D
    J Cell Mol Med; 2023 Oct; 27(19):2995-3008. PubMed ID: 37679999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.